Federation des caisses Desjardins du Quebec’s Akebia Therapeutics AKBA Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$208	Hold	150	–	–	﹤0.01%	2875
2025 Q4	$242	Hold	150	–	–	﹤0.01%	2775
2025 Q3	$410	Hold	150	–	–	﹤0.01%	2743
2025 Q2	$546	Hold	150	–	–	﹤0.01%	2562
2025 Q1	$288	Hold	150	–	–	﹤0.01%	2544
2024 Q4	$285	Hold	150	–	–	﹤0.01%	2434
2024 Q3	$198	Hold	150	–	–	﹤0.01%	2456
2024 Q2	$153	Hold	150	–	–	﹤0.01%	2351
2024 Q1	$275	Hold	150	–	–	﹤0.01%	2285
2023 Q4	$186	Hold	150	–	–	﹤0.01%	2266
2023 Q3	$171	Hold	150	–	–	﹤0.01%	2282
2023 Q2	$137	Hold	150	–	–	﹤0.01%	2260
2023 Q1	$84	Hold	150	–	–	﹤0.01%	2290
2022 Q4	$87	Hold	150	–	–	﹤0.01%	2429
2022 Q3	$47	Hold	150	–	–	﹤0.01%	2483
2022 Q2	$53	Hold	150	–	–	﹤0.01%	2516
2022 Q1	$108	Hold	150	–	–	﹤0.01%	2525
2021 Q4	$339	Hold	150	–	–	﹤0.01%	2481
2021 Q3	$432	Hold	150	–	–	﹤0.01%	2497
2021 Q2	$569	Hold	150	–	–	﹤0.01%	2460
2021 Q1	$508	Hold	150	–	–	﹤0.01%	2397
2020 Q4	$420	Hold	150	–	–	﹤0.01%	2274
2020 Q3	$376	Hold	150	–	–	﹤0.01%	2097
2020 Q2	$2.04K	Hold	150	–	–	﹤0.01%	1943
2020 Q1	$1.14K	Hold	150	–	–	﹤0.01%	2056
2019 Q4	$948	Hold	150	–	–	﹤0.01%	2206
2019 Q3	$588	Hold	150	–	–	﹤0.01%	2192
2019 Q2	$726	Sell	150 -470	-76%	-$2.67K	﹤0.01%	2171
2019 Q1	$5.08K	Buy	620 +470	+313%	+$3.23K	﹤0.01%	1804
2018 Q4	$830	Buy	+150	New	+$1.17K	﹤0.01%	1969
2018 Q1	–	Sell	-31,161	Closed	-$462K	–	2151
2017 Q4	$462K	Buy	31,161 +6,612	+27%	+$110K	0.01%	780
2017 Q3	$484K	Buy	+24,549	New	+$377K	0.01%	739

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Federation des caisses Desjardins du Quebec's AKBA Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 150 shares worth $208. The position accounts for ﹤0.01% of the portfolio, ranked #2875.

Federation des caisses Desjardins du Quebec first reported a position in AKBA in Q3 2017 and has held it in 32 quarters since. The position peaked at $484K in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Federation des caisses Desjardins du Quebec held 150 shares of Akebia Therapeutics worth $208 as of Q1 2026.
Federation des caisses Desjardins du Quebec left its Akebia Therapeutics share count unchanged in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2875 holding.
Federation des caisses Desjardins du Quebec first reported a position in Akebia Therapeutics in Q3 2017 and has held it in 32 quarters since.
Federation des caisses Desjardins du Quebec's Akebia Therapeutics position peaked at $484K in Q3 2017.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.